LinkedIn·Tuesday, 18 August 2026·8d ago

Revolutionize your CRC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions and alleviate patient anxiety*! Rapidly identify…

Biocartis

48,302 followers

Revolutionize your CRC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions and alleviate patient anxiety*! Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, with results in only three hours. Ensure they receive the most effective treatment without delay. 👉 Read more https://lnkd.in/dgR23Qae Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #MSI #RAS #NRAS #KRAS #BRAF #immunotherapy #ColorectalCancer #CRC *Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham. The content of this post is only applicable to Idylla™ KRAS & NRAS-BRAF Mutation Tests and Idylla™ MSI & CDx MSI Tests which are CE-marked in Europe; Idylla™ MSI Test which is cleared in the US under K211181 for Lynch Syndrome; and Idylla™ CDx MSI Test which is approved in the US under P250005. Idylla™ KRAS & NRAS-BRAF Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.